Latest Featured Products

Discover ioSensory Neurons, precision reprogrammed human iPSC-derived nociceptors from bit.bio. Don’t settle for non-human in vitro models or long, complex differentiation protocols that require toxic reagents. Start running reliable nociception assays with ioSensory Neurons today.

Label-free biosensor technologies have emerged as a promising approach to identify high-value hits with a strong likelihood of success as a therapeutic. Unlike traditional approaches of drug discovery, they are fast, sensitive, and come with improved success rates towards high-value drug candidates.

Designed with sustainability in mind, the Avio® 220 Max is a compact, hybrid simultaneous ICP-OES with multiple waste-reducing technologies.

From the quickest start-up time on the market to reduced argon consumption, the Avio 220 Max is ideal for labs with low-to-medium throughput requirements.

The LANEXO® lab inventory manager lets you easily register, track, and monitor all consumables. Upgrade to an ultra-efficient, audit-ready lab.

The Revio system adds affordability, high throughput, and ease of use to a foundation of long
reads, exceptional accuracy, and direct methylation detection. Get reads that are tens of
kilobases in length with >Q30 scores and complete phased genomes for <$1,000, all with 50%
fewer consumables.

CARNK cell therapies are novel therapeutic options developed with the aim to overcome some limitations of CART cell therapies, such as therapy induced side effects.

The PrismA ELISA kit is an enzyme-linked immunosorbent assay designed to measure residual ligand leakage when using MabSelect PrismA™ chromatography resin and Fibro™ PrismA chromatography adsorbers. PrismA ELISA kit is the only commercial kit specifically designed for use with MabSelect PrismA™ resins and Fibro™ PrismA adsorbers.

With the CellCelector Flex single cell and colony picking platform, you can now effectively assess and verify your clones before deciding which ones to choose. In less than one week, you will obtain monoclonal, viable, and productive colonies from your pool of single cells. Instead of relying on large quantities of plates to produce a winner you can now use actual data to reliably predict the future of your clones. This saves consumable and media costs, incubator space, and most of all valuable time by avoiding missteps, a second cloning round, and unnecessary procedures

As life science monitoring service providers for 30+ years, our team will address all of your equipment, environmental, and facility monitoring needs with 24/7 support to safeguard critical scientific assets.

Ductal carcinoma in situ (DCIS), cancer cell growth that starts in the milk ducts, is the most common form of breast cancer. However, why some DCIS progress to invasive carcinoma but others remain innocuous is still unclear. In a recent study, three groundbreaking technologies—Chromium Single Cell, Visium Spatial, and Xenium In Situ—were used to achieve a deeper understanding into the biology of a single, breast cancer patient-derived, FFPE tissue block.